Citations 1
A phase (Ph) 1/2 trial of rituximab (RX), imprime PGG (IP), and alemtuzumab (AL) in the early treatment of patients (Pts) with high risk chronic lymphocytic leukemia (CLL).
Bose, Nandita , LaPlant, Betsy, Ottoson, Nadine, Leonardo, Steven , Jonas, Adria, Huhn, Richard D. , Braun, Ada, Ansell, Stephen M. , Zent, Clive S. , Weiner, George J. , Jonas, Adria Bykowski
Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 7078-7078
